A- A A+

USA. TAG – Treatment Action Group celebrates 30th anniversary

TAG was formed thirty years ago in January 1992 by a group of HIV activists from the AIDS Coalition to Unleash Power (ACT UP)/New York and its Treatment and Data Committee. 

TAG’s cofounders — Barbara Hughes, Garance Franke-Ruta, Gregg Gonsalves, Peter Staley and Mark Harrington among them — believed it was essential to form a community organization with a full-time focus on speeding up AIDS research, advocating for increased funding, and ensuring that people with HIV and at risk for it had access to and information about treatments that could save their lives. 

In those dark days at the height of the AIDS crisis, few could have imagined just how much TAG would help to revolutionize the field. In its early years, TAG pushed to overhaul clinical trials to produce quicker and more reliable answers about whether new drugs and combinations actually worked. By 1996, that activism led to the breakthrough discovery that combination HIV treatment could reduce viral load to undetectable levels, protecting health and prolonging life. (TAG, USA, Juni 2022)

https://www.treatmentactiongroup.org/support-us/tag-at-30

Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression

Hosseini-Hooshyar, Samira et al.

The Lancet HIV, Volume 9, Issue 6, e414 - e427 

https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00077-7/fulltext

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial

Houser, Katherine V. et al.

eClinicalMedicine, Volume 0, Issue 0, 101477 

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00207-3/fulltext

Impact of illicit opioid use on markers of monocyte activation and systemic inflammation in people living with HIV. 

Kholodnaia A, So-Armah K, Cheng D, Gnatienko N, Patts G, Samet JH, et al. (2022) 

PLoS ONE 17(5): e0265504. doi.org/10.1371/journal.pone.0265504

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265504

Impact of Co-occurring Drug Use, Hazardous Alcohol Use, and Mental Health Disorders on Drug Use Patterns in People With HIV and Hepatitis C Virus Infection. 

McCormick S, Ward KM, Sutcliffe CG, Irvin R, Chander G, Brooner RK, Mehta SH, Thomas DL, Sulkowski M, Falade-Nwulia O. 

Open Forum Infect Dis. 2021 Oct 19;8(11):ofab520. doi: 10.1093/ofid/ofab520. PMID: 35559126; PMCID: PMC9088503.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088503/

A contingency management approach for treatment of methamphetamine use disorder and human immunodeficiency virus antiretroviral treatment adherence in pregnancy to prevent mother-to-child transmission: a case report. 

Turner S, Nader M, Lurie E. 

J Med Case Rep. 2022 Apr 27;16(1):165. doi: 10.1186/s13256-022-03391-x. PMID: 35473945; PMCID: PMC9044665.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044665/

HIV among migrants in precarious circumstances in the EU and European Economic Area

Nöstlinger, Christiana et al.

The Lancet HIV, Volume 0, Issue 0 

https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00032-7/fulltext

Deutschland. Finde HIV-Einrichtungen in deiner Nähe

Herzlich willkommen auf kompass.hiv – dem Adressverzeichnis rund um HIV/Aids und sexuelle Gesundheit. Hier gibt es Adressen von Aidshilfen, Checkpoints und anderen Beratungs-, Test- oder Selbsthilfe-Stellen. Bei Wohn-, Reha- und Pflegeprojekten informieren wir auch detailliert über die Einrichtungen und deren Angebote. (DAH – Deutsche AIDS-Hilfe, Stand 11.04.2022)

https://www.kompass.hiv/de

Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. 

Lanièce Delaunay C, Maheu-Giroux M, Marathe G, Saeed S, Martel-Laferrière V, Cooper CL, Walmsley S, Cox J, Wong A, Klein MB; Canadian Coinfection Cohort investigators.

Int J Drug Policy. 2022 Feb 23;103:103627. doi: 10.1016/j.drugpo.2022.103627. Epub ahead of print. PMID: 35218989.

https://www.sciencedirect.com/science/article/pii/S0955395922000470

First mRNA HIV Vaccine Clinical Trial Launches. 

Abbasi J. 

JAMA. 2022;327(10):909. doi:10.1001/jama.2022.2699

https://jamanetwork.com/journals/jama/fullarticle/2789679

Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: cross-sectional and longitudinal analyses. 

Jones, TPW, Lampe, FC, Arenas-Pinto, A, et al; for the ASTRA Study Group. 

HIV Med. 2022; 23: 209– 226. doi.org/10.1111/hiv.13156

https://onlinelibrary.wiley.com/doi/10.1111/hiv.13156

Acceptability of a HIV self-testing program among people who use illicit drugs. 

Peiper NC, Shamblen S, Gilbertson A, Guest G, Kopp M, Guy L, Rose MR. 

Int J Drug Policy. 2022 Mar 4;103:103613. doi: 10.1016/j.drugpo.2022.103613. Epub ahead of print. PMID: 35255391.

https://www.sciencedirect.com/science/article/pii/S0955395922000330

Stigma and ART initiation among people with HIV and a lifetime history of illicit drug use in Saint-Petersburg, Russia-A prospective cohort analysis. 

Vetrova M, Lodi S, Rateau L, Patts G, Blokhina E, Palatkin V, Yaroslavtseva T, Toussova O, Bushara N, Bendiks S, Gnatienko N, Krupitsky E, Lioznov D, Samet JH, Lunze K. 

Int J Drug Policy. 2022 Feb 5;102:103600. doi: 10.1016/j.drugpo.2022.103600. Epub ahead of print. PMID: 35134598.

https://www.sciencedirect.com/science/article/pii/S0955395922000202

The impact of peer support on testing, linkage to and engagement in HIV care for people who inject drugs in Indonesia: qualitative perspectives from a community-led study. 

Iryawan AR, Stoicescu C, Sjahrial F, Nio K, Dominich A. 

Harm Reduct J. 2022 Feb 11;19(1):16. doi: 10.1186/s12954-022-00595-8. PMID: 35148776; PMCID: PMC8832667.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832667/

Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV. 

Cheng CY, Ku SY, Lin YC, Chen CP, Cheng SH, Lin IF. 

Viruses. 2022 Feb 21;14(2):439. doi: 10.3390/v14020439. PMID: 35216032; PMCID: PMC8874599.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874599/

HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. 

Korthuis, PT, Cook, RR, Lum, PJ, Waddell, EN, Tookes, H, Vergara-Rodriguez, P, et al. 

Addiction. 2022; 1– 11. doi.org/10.1111/add.15836 

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15836

Social Support is Key to Retention in Care during Covid-19 Pandemic among Older People with HIV and Substance Use Disorders in Ukraine. 

Rozanova J, Shenoi S, Zaviryukha I, Zeziulin O, Kiriazova T, Rich K, Mamedova E, Yariy V. 

Subst Use Misuse. 2020;55(11):1902-1904. doi: 10.1080/10826084.2020.1791183. Epub 2020 Jul 15. PMID: 32666857; PMCID: PMC7523433.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523433/

Anxiety, depression, and quality of life among HIV positive injection drug users in Ukraine, 2017. 

Vasylyev M, Davtyan H, Denisiuk O, Chadwick Jayaraj J, Koval T, Piddubna A, Sluzhynska M, Sluzhynska O, Mulcahy F. 

J Infect Dev Ctries. 2019 Jul 31;13(7.1):111S-117S. doi: 10.3855/jidc.11295. PMID: 32065813.

https://jidc.org/index.php/journal/article/view/32065813

Assessing the influence of conflict on the dynamics of sex work and the HIV and HCV epidemics in Ukraine: protocol for an observational, ethnographic, and mathematical modeling study. 

Becker M, Balakireva O, Pavlova D, Isac S, Cheuk E, Roberts E, Forget E, Ma H, Lazarus L, Sandstrom P, Blanchard J, Mishra S, Lorway R, Pickles M; Dynamics Study Team. 

BMC Int Health Hum Rights. 2019 May 20;19(1):16. doi: 10.1186/s12914-019-0201-y. PMID: 31109323; PMCID: PMC6528269.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528269/

Stigma reduction is key to improving the HIV care continuum

Poteat, Tonia C et al.

The Lancet HIV, Volume 9, Issue 3, e144 - e145 

https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00323-4/fulltext

Global assessment of existing HIV and key population stigma indicators: A data mapping exercise to inform country-level stigma measurement. 

Lyons C, Bendaud V, Bourey C, Erkkola T, Ravichandran I, Syarif O, et al. (2022) 

PLoS Med 19(2): e1003914. doi.org/10.1371/journal.pmed.1003914

https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003914

A highly virulent variant of HIV-1 circulating in the Netherlands. 

Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C; Netherlands ATHENA HIV Observational Cohort†; BEEHIVE Collaboration†, et al. 

Science. 2022 Feb 4;375(6580):540-545. doi: 10.1126/science.abk1688. Epub 2022 Feb 3. PMID: 35113714.

https://www.science.org/doi/10.1126/science.abk1688

Virulente HIV-Variante aus den Niederlanden führt (unbehandelt) schneller zu Aids

Oxford – Britische Forscher haben eine Variante des HI-Virus entdeckt, die sich schneller im Körper vermehrt und das Immunsystem unbehandelt bereits nach 9 Monaten irreversibel schädigen kann. (aerzteblatt.de, 04.02.2022)

https://www.aerzteblatt.de/nachrichten/131538/Virulente-HIV-Variante-aus-den-Niederlanden-fuehrt-(unbehandelt)-schneller-zu-Aids

New Yorker Patientin durch Stammzellen aus Nabelschnurblut von HIV geheilt

Los Angeles – Mediziner haben an einer Klinik in New York eine Frau mit Stammzellen aus Nabelschnurblut von einer HIV-Infektion kuriert. Die Behandlung wurde mit einer konventionellen Knochenmarktransplantation kombiniert, um die Zeit bis zur Bildung eines neuen Immunsystems zu beschleunigen. (aerzteblatt.de, 16.02.2022)

https://www.aerzteblatt.de/nachrichten/131876/New-Yorker-Patientin-durch-Stammzellen-aus-Nabelschnurblut-von-HIV-geheilt

Luc Montagnier, Nobel-Winning Co-Discoverer of H.I.V., Dies at 89

(New York Times, USA, 10.02.2022)

https://www.nytimes.com/2022/02/10/science/luc-montagnier-dead.html

Nobelpreisträger und HIV-Entdecker Luc Montagnier gestorben

Paris – Der Nobelpreisträger und französische Entdecker des Aids-Erregers HIV, Luc Montagnier, ist tot. Der Mediziner starb im Alter von 89 Jahren, wie das Wissenschaftsministerium in Paris gestern mitteilte. (aerzteblatt.de, 11.02.2022)

https://www.aerzteblatt.de/nachrichten/131743/Nobelpreistraeger-und-HIV-Entdecker-Luc-Montagnier-gestorben

Acceptability, feasibility, and pilot results of the tele-harm reduction intervention for rapid initiation of antiretrovirals among people who inject drugs. 

Tookes HE, Bartholomew TS, Suarez E, Ekowo E, Ginoza M, Forrest DW, Serota DP, Rodriguez A, Kolber MA, Feaster DJ, Mooss A, Boyd D, Sternberg C, Metsch LR. 

Drug Alcohol Depend. 2021 Dec 1;229(Pt A):109124. doi: 10.1016/j.drugalcdep.2021.109124. Epub 2021 Oct 27. PMID: 34781096.

https://www.sciencedirect.com/science/article/pii/S0376871621006190

Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency. 

Gornalusse GG, Vojtech LN, Levy CN, Hughes SM, Kim Y, Valdez R, Pandey U, Ochsenbauer C, Astronomo R, McElrath J, Hladik F. 

Viruses. 2021 Jul 27;13(8):1472. doi: 10.3390/v13081472. PMID: 34452338; PMCID: PMC8402857.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402857/

Erste klinische Tests eines mRNA-Impfstoffes gegen Aids

Washington – In den USA ist der Test eines Aids-Impfstoffes auf Grundlage der mRNA-Technologie an Menschen angelaufen. In der Phase-I sei der Impfstoff 56 gesunden, HIV-negativen Men­schen verab­reicht worden, teilten das US-Biotechnologie-Unternehmen Moderna und die Organisation International Aids Vaccine Initiative gestern mit. (aerzteblatt.de, 28.01.2022)

https://www.aerzteblatt.de/nachrichten/131331/Erste-klinische-Tests-eines-mRNA-Impfstoffes-gegen-Aids

Associations amongst form of cocaine used (powder vs crack vs both) and HIV-related outcomes. 

Liu Y, Richards VL, Gebru NM, Spencer EC, Cook RL. 

Addict Behav Rep. 2021 Sep 4;14:100374. doi: 10.1016/j.abrep.2021.100374. PMID: 34938835; PMCID: PMC8664776.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664776/

  1. Injection drug use practices and HIV infection among people who inject drugs in Kigali, Rwanda: a cross-sectional study.
  2. Prevalence of HIV, Hepatitis C and its related risk behaviours among women who inject drugs in the Kathmandu Valley, Nepal: a cross-sectional study. 
  3. INPUD Summary Report: WHO Key Populations' Values & Preferences for HIV, Hepatitis and STIs Services 
  4. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis
  5. "That same stigma...that same hatred and negativity:" a qualitative study to understand stigma and medical mistrust experienced by people living with HIV diagnosed with COVID-19.